ArticleThrombosis journal2025
Long-term patency of the transjugular intrahepatic portosystemic shunt for portal and superior mesenteric vein thrombosis.
Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis retrospective study evaluated the long-term patency of transjugular intrahepatic portosystemic shunt (TIPS) placement and identified predictors of shunt dysfunction in patients with portal and superior mesenteric vein thrombosis (PSVT).
methodsFrom January 2018 to January 2024, patients with symptomatic PSVT who underwent TIPS were enrolled. Clinical variables, imaging features, adverse events, and clinical outcomes were recorded. The cumulative rate of TIPS patency rates were calculated using the Kaplan-Meier method, with subgroup comparisons performed by the log-rank test. Independent predictors of shunt dysfunction were identified via Cox regression analysis.
resultsForty-nine patients (mean age 47.8 ± 12.5 years; 79.6% male) were successfully treated with TIPS. Among them, 69.4% had cirrhosis and 49.0% had hepatitis B virus infection, with cirrhosis-related portal hypertension being the most common etiology of thrombosis. The 6-, 12-, and 24-month primary patency rates were 70.8% (95% CI: 59.0–85.0%), 66.4% (95% CI: 54.3–81.3%), and 56.5% (95% CI: 43.7–73.1%), respectively. Multivariate analysis identified sufficient inflow (patency of the splenic vein or an inflow vein diameter > 8 mm) and the use of covered stents in the main portal vein as independent predictors of TIPS patency.
conclusionsTIPS can be safely performed in patients with PSVT. Adequate inflow and the use of covered stents in the main portal vein are important factors for long-term TIPS patency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.